CA2412205C - Medicinal product package for eradication therapy - Google Patents
Medicinal product package for eradication therapy Download PDFInfo
- Publication number
- CA2412205C CA2412205C CA2412205A CA2412205A CA2412205C CA 2412205 C CA2412205 C CA 2412205C CA 2412205 A CA2412205 A CA 2412205A CA 2412205 A CA2412205 A CA 2412205A CA 2412205 C CA2412205 C CA 2412205C
- Authority
- CA
- Canada
- Prior art keywords
- blister
- container
- medicinal product
- package
- blister cards
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D83/00—Containers or packages with special means for dispensing contents
- B65D83/08—Containers or packages with special means for dispensing contents for dispensing thin flat articles in succession
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
- A61J1/035—Blister-type containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
- A61J7/04—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D5/00—Rigid or semi-rigid containers of polygonal cross-section, e.g. boxes, cartons or trays, formed by folding or erecting one or more blanks made of paper
- B65D5/42—Details of containers or of foldable or erectable container blanks
- B65D5/4204—Inspection openings or windows
Abstract
The object of the present invention is to provide a medicinal product package which is suitable for microbe eradication therapy and with which the patient's compliance is increased and thus the result of therapy is improved.
Description
Medicinal product package for eradication therapy Technical field The present invention relates to a novel medicinal product package for housing blister cards for eradication therapy. Patient compliance can be noticeably increased with this package.
Prior art For the treatment of Helicobacter pylori disorders, the BDA (Professional association of general practitioners in Germany: Kunzel D.; BDA-Leitfaden: Unklare Oberbauchbeschwerden; published by:
Kybermed GmbH, Emsdetten, 1st edition, Emsdetten 1999) and the ESPCG (European Society for Primary Care Gastroenterology: Rubin G.P.; European Journal of General Practice, Vol. 5, 1999) recommend a combination therapy in which a proton pump inhibitor is administered at the same time as two different antibiotics. It is possible with such a triple therapy to achieve impressive eradication results (Huang J.Q., Hunt R. H.; GUT Vol. 45, Suppl. 1, 1999, i40).
The disadvantage of such a triple therapy is that, if the desired result of therapy is to be achieved, the patient has to swallow several tablets, often of considerable size, several times a day, normally two to three times. It is additionally necessary for intake generally to take place over a lengthy period of about seven to fourteen days. For successful treatment, a patient must show great compliance (adherence to therapy, i.e. compliance with a therapeutic instruction), and he must therefore adhere to the preset tablet composition and time of intake. Experience has shown that compliance by the patient is often less than expected without encouraging measures. Tablets are often taken at the wrong time, or intake is completely or partly forgotten, or the patient terminates the therapy before using all the tablets provided in the package. The risk of premature discontinuation of the therapy particularly applies to Helicobacter pylori therapy because there is a rapid improvement in the patient's wellbeing after the start of the therapy. The consequence of premature discontinuation of the therapy is, however, that complete eradication of the microbe is not achieved and, in addition, the microbe may develop resistance to the antibiotics used. Without measures for encouraging compliance, therefore, distinctly poorer results of therapy are to be expected.
EP-391 459 B1 describes a medicament package for improving compliance with a base in which a plurality of blister cards is stacked horizontally one on top of the other in a defined sequence, and with a lid which covers the base. The lid is movable into an open position whereby access to the uppermost blister card is provided. This makes it possible, in complex treatments, to avoid the patient taking a wrong blister card and consequently taking the wrong medicinal product at a given time.
WO 02/00161 _ 2 _ PCT/EPO1/07148 Description of the invention The object of the present invention is to provide a medicinal product package which is suitable for microbe eradication therapy and with which the patient's compliance is increased and thus the result of therapy is improved.
This object is achieved by a medicinal product package where the package comprises: (a) a multiplicity of blister cards of generally uniform planar dimensions, where the blister cards are disposed .in a stack with their principal dimensions oriented generally horizontally and arranged in order of card use, with the first card to be used lying right at the bottom and (b) a container which houses the stack of blister cards, where the container has an access for removing the blister lying right at the bottom, and where the container has means for indicating the remaining days of treatment as a function of the blister cards removed.
The use of the medicinal product package of the invention in microbe eradication therapy leads to distinctly increased compliance by the patient, and the package has proved to be particularly suitable in therapy for eradication of Helicobacter pylori using pantoprazole or other proton pump inhibitors such as, for example, omeprazole in combination with antibiotics.
The medicinal product package comprises a container whose shape and dimension is suitable for housing blister cards of the usual size. The container preferably has a shape customary for secondary medicinal product packages, for example the shape of a cuboid. The container is preferably fabricated from materials which are normally used for producing secondary medicinal product packages, such as, for example, paperboard. A multiplicity of blister cards is stacked one on top of the other oriented horizontally in the container. The container additionally has means for creating an access for removing the blister card lying right at the bottom of the stack of blister cards in each case. It is thus possible for .the.container to have, for example, first zones which can be detached from the remainder of the container. These first zones preferably have dimensions such that detachment thereof from the remainder of the container creates an opening through which, when the container is correctly oriented, only the blister card lying right at the bottom can be removed. With containers fabricated from a suitable paperboard, these first zones may comprise perforated marginal lines which make it possible easily to detach the first zones from the remainder of the container. The container additionally has means for indicating the remaining days of treatment depending on the number of removed blister cards. For this purpose, the container may have, for example, a second zone which makes it possible for a viewer to establish the number of days of treatment still remaining, as a function of the quantity of blister cards present in the package. For example, the second zone may be a vertically oriented; elongate, transparent zone in a side wall of the container. The transparent zone may be, for example, an WO 02/00161 _ 3 _ PCT/EPO1/07148 opening. A scale with the number of days of treatment, as a function of the height of the stack of blister cards, is printed horizontally on the transparent zone or on the container adjacent to the elongate transparent zone. If all the blister cards are still present in the package, then the blister card lying uppermost in the container is located horizontally in line with the printed number which corresponds to the total number of days of treatment. After removal of a first blister card, the total height of the stack of blister cards is lower, and the topmost blister card is located horizontally in line with the printed number corresponding to the total number of days of treatment minus one. After removal of a second blister card, the total height of the stack of blister cards is lowered, and the topmost blister card is located horizontally in line with the printed number corresponding to the total number of days of treatment minus two etc. If required, a leaflet with information for the patient may also be located in the container underneath the stack of blister cards and must then, where appropriate, first be removed before the blister card lying right at the bottom can be removed. The container is fabricated in a conventional way familiar to the skilled worker.
The blister card can likewise be fabricated in a conventional way known to the skilled worker. Thus, for example, it is possible to insert between two base plates made of a suitable material, such as plastic or board, two other layers of material, one of which forms the blister cavities and the other forms the easily pierced blister base, or it is possible to choose a two-layer structure of the blister in which the cavities are incorporated into the upper layer and the latter is then coated from below with another layer of an easily pierced material, which closes the openings in which the medicaments are located.
The usual materials known to a skilled worker for producing commercially available blisters are used, such as, for example, laminated aluminum sheets, PVC (polyvinyl chloride) or PVdC (polyvinylidene chloride) sheets or combinations thereof or PP (polypropylene) sheets or combinations or laminations of said materials.
Each blister card preferably contains the medicaments to be taken on one day of treatment. If the medicaments are to be taken at different times of day, the medicaments can be disposed in different sections on the blister card according to the different ranges of times of day at which the medicaments are to be taken (for example morning and evening or morning, midday and evening). The blister cavities for the medicaments to be taken together at a particular time of day are accommodated in the respective range of times of day. The various times of day are, of course, also put on the blister in a clearly visible way. It is also possible, of course, for example to indicate a period in which the medicaments are to be taken, for example stating the times.
The daily sections may represent one line of the blister card, and the times of day are then identified in chronological sequence in this column.
WO 02/00161 _ ~, _ PCT/EPO1/07148 Medicaments which must be taken together at a particular time of day are placed together at the appropriate time on the blister card, preferably a narrow distance apart, allowing them to be pushed out of the blister easily, and having the effect that removal of the dosage form from the blister is not forgotten.
The individual daily sections and, if required, the time of day sections can be detached from one another owing to perforation. The patient is thus able after removal of the medicaments to detach the corresponding section and obtain a more easily inspected blister card. This also reduces the probability of medicaments whose intake has been forgotten subsequently being taken, which may lead, for example, to.unwanted high medicament concentrations.
The number of blister cards present in the medicinal product package of the invention depends on the duration of therapy and the number of medicaments to be taken. The number of blister cards is normally four to twenty, preferably seven to fourteen.
The medicinal product package can advantageously be employed in the therapy of Helicobacter pylori disorders. Preferably employed as active ingredients in such cases are proton pump inhibitors such as pantoprazole, omeprazole and other proton pump inhibitors known to the skilled worker in combination with antibiotics such as amoxicillin, clarithromycin, azithromycin, tetracycline, metronidazole and tinidazole. The proton pump inhibitor is moreover preferably combined with two different antibiotics (triple therapy). Examples which may be mentioned are combination of proton pump inhibitor with amoxicillin and clarithromycin, combination of proton pump inhibitor with clarithromycin and metronidazole, and combination with proton pump inhibitor with amoxicillin and metronidazole. The active ingredients are in these cases employed in the amount customary and necessary for the treatment. The therapy is normally carried out for a period of from seven to fourteen days.
The invention is now explained by means of the figures which show an exemplary embodiment of a medicinal product package of the invention employed for Helicobacter pylori therapy.
Fig. 1 shows a medicinal product package 1 of the invention made of paperboard in the closed state for a seven-day therapy for Helicobacter pylori eradication, employing as active ingredients pantoprazole in combination with amoxicillin and clarithromycin. The package 1 has a first zone 2 which is intended to be detached and is surrounded by a perforated line 3. As means for indicating the remaining days of treatment, the package has a vertically oriented elongate opening 4. Through the opening 4 it is possible for a viewer to see the seven blister cards 5 with the daily dose of the medicaments employed in the package 1. A scale 6 is printed on the container 1 in connection with the elongate opening 4 and indicates the remaining days of treatment as a function of the height of the stack of blister cards 5.
WO 02/00161 , 5 _ PCT/EPO1/07148 Fig. 2 shows the medicinal product package 1 after detachment of the first zone 2 along the perforated line 3. Underneath the stack of blister cards 5 there is a leaflet 7 with information for the patient, which is accessible through the removal opening 8 which has been produced.
Fig. 3 shows the medicinal product package 1 after removal of the leaflet 7 with the information for the patient and after removal of two blister cards 5. The stack of blister cards 5 still contains five blister cards for the remaining 5 days of treatment. The topmost blister card 5 in the stack is now in a horizontal location in line with the printed "5 days left".
Fig. 4 shows a blister card 5 for housing the daily dose of the medicaments employed. The blister card is divided into two time of day of sections 9, 10, the sections accommodating the medicaments to be taken in the morning and evening respectively. Each time of day section 9, 10 comprises three blister cavities 11 accommodating pantoprazole (40 mg), amoxicillin (1000 mg) and clarithromycin (500 mg).
The time of day sections 9, 10 are designed to be separable by a perforation 12.
Prior art For the treatment of Helicobacter pylori disorders, the BDA (Professional association of general practitioners in Germany: Kunzel D.; BDA-Leitfaden: Unklare Oberbauchbeschwerden; published by:
Kybermed GmbH, Emsdetten, 1st edition, Emsdetten 1999) and the ESPCG (European Society for Primary Care Gastroenterology: Rubin G.P.; European Journal of General Practice, Vol. 5, 1999) recommend a combination therapy in which a proton pump inhibitor is administered at the same time as two different antibiotics. It is possible with such a triple therapy to achieve impressive eradication results (Huang J.Q., Hunt R. H.; GUT Vol. 45, Suppl. 1, 1999, i40).
The disadvantage of such a triple therapy is that, if the desired result of therapy is to be achieved, the patient has to swallow several tablets, often of considerable size, several times a day, normally two to three times. It is additionally necessary for intake generally to take place over a lengthy period of about seven to fourteen days. For successful treatment, a patient must show great compliance (adherence to therapy, i.e. compliance with a therapeutic instruction), and he must therefore adhere to the preset tablet composition and time of intake. Experience has shown that compliance by the patient is often less than expected without encouraging measures. Tablets are often taken at the wrong time, or intake is completely or partly forgotten, or the patient terminates the therapy before using all the tablets provided in the package. The risk of premature discontinuation of the therapy particularly applies to Helicobacter pylori therapy because there is a rapid improvement in the patient's wellbeing after the start of the therapy. The consequence of premature discontinuation of the therapy is, however, that complete eradication of the microbe is not achieved and, in addition, the microbe may develop resistance to the antibiotics used. Without measures for encouraging compliance, therefore, distinctly poorer results of therapy are to be expected.
EP-391 459 B1 describes a medicament package for improving compliance with a base in which a plurality of blister cards is stacked horizontally one on top of the other in a defined sequence, and with a lid which covers the base. The lid is movable into an open position whereby access to the uppermost blister card is provided. This makes it possible, in complex treatments, to avoid the patient taking a wrong blister card and consequently taking the wrong medicinal product at a given time.
WO 02/00161 _ 2 _ PCT/EPO1/07148 Description of the invention The object of the present invention is to provide a medicinal product package which is suitable for microbe eradication therapy and with which the patient's compliance is increased and thus the result of therapy is improved.
This object is achieved by a medicinal product package where the package comprises: (a) a multiplicity of blister cards of generally uniform planar dimensions, where the blister cards are disposed .in a stack with their principal dimensions oriented generally horizontally and arranged in order of card use, with the first card to be used lying right at the bottom and (b) a container which houses the stack of blister cards, where the container has an access for removing the blister lying right at the bottom, and where the container has means for indicating the remaining days of treatment as a function of the blister cards removed.
The use of the medicinal product package of the invention in microbe eradication therapy leads to distinctly increased compliance by the patient, and the package has proved to be particularly suitable in therapy for eradication of Helicobacter pylori using pantoprazole or other proton pump inhibitors such as, for example, omeprazole in combination with antibiotics.
The medicinal product package comprises a container whose shape and dimension is suitable for housing blister cards of the usual size. The container preferably has a shape customary for secondary medicinal product packages, for example the shape of a cuboid. The container is preferably fabricated from materials which are normally used for producing secondary medicinal product packages, such as, for example, paperboard. A multiplicity of blister cards is stacked one on top of the other oriented horizontally in the container. The container additionally has means for creating an access for removing the blister card lying right at the bottom of the stack of blister cards in each case. It is thus possible for .the.container to have, for example, first zones which can be detached from the remainder of the container. These first zones preferably have dimensions such that detachment thereof from the remainder of the container creates an opening through which, when the container is correctly oriented, only the blister card lying right at the bottom can be removed. With containers fabricated from a suitable paperboard, these first zones may comprise perforated marginal lines which make it possible easily to detach the first zones from the remainder of the container. The container additionally has means for indicating the remaining days of treatment depending on the number of removed blister cards. For this purpose, the container may have, for example, a second zone which makes it possible for a viewer to establish the number of days of treatment still remaining, as a function of the quantity of blister cards present in the package. For example, the second zone may be a vertically oriented; elongate, transparent zone in a side wall of the container. The transparent zone may be, for example, an WO 02/00161 _ 3 _ PCT/EPO1/07148 opening. A scale with the number of days of treatment, as a function of the height of the stack of blister cards, is printed horizontally on the transparent zone or on the container adjacent to the elongate transparent zone. If all the blister cards are still present in the package, then the blister card lying uppermost in the container is located horizontally in line with the printed number which corresponds to the total number of days of treatment. After removal of a first blister card, the total height of the stack of blister cards is lower, and the topmost blister card is located horizontally in line with the printed number corresponding to the total number of days of treatment minus one. After removal of a second blister card, the total height of the stack of blister cards is lowered, and the topmost blister card is located horizontally in line with the printed number corresponding to the total number of days of treatment minus two etc. If required, a leaflet with information for the patient may also be located in the container underneath the stack of blister cards and must then, where appropriate, first be removed before the blister card lying right at the bottom can be removed. The container is fabricated in a conventional way familiar to the skilled worker.
The blister card can likewise be fabricated in a conventional way known to the skilled worker. Thus, for example, it is possible to insert between two base plates made of a suitable material, such as plastic or board, two other layers of material, one of which forms the blister cavities and the other forms the easily pierced blister base, or it is possible to choose a two-layer structure of the blister in which the cavities are incorporated into the upper layer and the latter is then coated from below with another layer of an easily pierced material, which closes the openings in which the medicaments are located.
The usual materials known to a skilled worker for producing commercially available blisters are used, such as, for example, laminated aluminum sheets, PVC (polyvinyl chloride) or PVdC (polyvinylidene chloride) sheets or combinations thereof or PP (polypropylene) sheets or combinations or laminations of said materials.
Each blister card preferably contains the medicaments to be taken on one day of treatment. If the medicaments are to be taken at different times of day, the medicaments can be disposed in different sections on the blister card according to the different ranges of times of day at which the medicaments are to be taken (for example morning and evening or morning, midday and evening). The blister cavities for the medicaments to be taken together at a particular time of day are accommodated in the respective range of times of day. The various times of day are, of course, also put on the blister in a clearly visible way. It is also possible, of course, for example to indicate a period in which the medicaments are to be taken, for example stating the times.
The daily sections may represent one line of the blister card, and the times of day are then identified in chronological sequence in this column.
WO 02/00161 _ ~, _ PCT/EPO1/07148 Medicaments which must be taken together at a particular time of day are placed together at the appropriate time on the blister card, preferably a narrow distance apart, allowing them to be pushed out of the blister easily, and having the effect that removal of the dosage form from the blister is not forgotten.
The individual daily sections and, if required, the time of day sections can be detached from one another owing to perforation. The patient is thus able after removal of the medicaments to detach the corresponding section and obtain a more easily inspected blister card. This also reduces the probability of medicaments whose intake has been forgotten subsequently being taken, which may lead, for example, to.unwanted high medicament concentrations.
The number of blister cards present in the medicinal product package of the invention depends on the duration of therapy and the number of medicaments to be taken. The number of blister cards is normally four to twenty, preferably seven to fourteen.
The medicinal product package can advantageously be employed in the therapy of Helicobacter pylori disorders. Preferably employed as active ingredients in such cases are proton pump inhibitors such as pantoprazole, omeprazole and other proton pump inhibitors known to the skilled worker in combination with antibiotics such as amoxicillin, clarithromycin, azithromycin, tetracycline, metronidazole and tinidazole. The proton pump inhibitor is moreover preferably combined with two different antibiotics (triple therapy). Examples which may be mentioned are combination of proton pump inhibitor with amoxicillin and clarithromycin, combination of proton pump inhibitor with clarithromycin and metronidazole, and combination with proton pump inhibitor with amoxicillin and metronidazole. The active ingredients are in these cases employed in the amount customary and necessary for the treatment. The therapy is normally carried out for a period of from seven to fourteen days.
The invention is now explained by means of the figures which show an exemplary embodiment of a medicinal product package of the invention employed for Helicobacter pylori therapy.
Fig. 1 shows a medicinal product package 1 of the invention made of paperboard in the closed state for a seven-day therapy for Helicobacter pylori eradication, employing as active ingredients pantoprazole in combination with amoxicillin and clarithromycin. The package 1 has a first zone 2 which is intended to be detached and is surrounded by a perforated line 3. As means for indicating the remaining days of treatment, the package has a vertically oriented elongate opening 4. Through the opening 4 it is possible for a viewer to see the seven blister cards 5 with the daily dose of the medicaments employed in the package 1. A scale 6 is printed on the container 1 in connection with the elongate opening 4 and indicates the remaining days of treatment as a function of the height of the stack of blister cards 5.
WO 02/00161 , 5 _ PCT/EPO1/07148 Fig. 2 shows the medicinal product package 1 after detachment of the first zone 2 along the perforated line 3. Underneath the stack of blister cards 5 there is a leaflet 7 with information for the patient, which is accessible through the removal opening 8 which has been produced.
Fig. 3 shows the medicinal product package 1 after removal of the leaflet 7 with the information for the patient and after removal of two blister cards 5. The stack of blister cards 5 still contains five blister cards for the remaining 5 days of treatment. The topmost blister card 5 in the stack is now in a horizontal location in line with the printed "5 days left".
Fig. 4 shows a blister card 5 for housing the daily dose of the medicaments employed. The blister card is divided into two time of day of sections 9, 10, the sections accommodating the medicaments to be taken in the morning and evening respectively. Each time of day section 9, 10 comprises three blister cavities 11 accommodating pantoprazole (40 mg), amoxicillin (1000 mg) and clarithromycin (500 mg).
The time of day sections 9, 10 are designed to be separable by a perforation 12.
Claims (9)
1. A medicinal product package (1) for improving compliance in microbe eradication therapy, where the package has: (a) a multiplicity of blister cards (5) of generally uniform planar dimensions, where the blister cards (5) are disposed in a stack with their principal dimensions oriented generally horizontally and arranged in order of card use, with the first card to be used lying right at the bottom and (b) a container which houses the stack of blister cards (5), where the container has an access for removing the blister lying right at the bottom, characterized in that the container has means for indicating the remaining days of treatment as a function of the blister cards (5) removed and where the means for indicating the remaining days of treatment as a function of the blister cards (5) removed is a vertically oriented, elongate, transparent zone (4) in a side wall of the container, and a scale (6) with the number of days of treatment as a function of the height of the stack of blister cards (5) is printed horizontally on the transparent zone (4) or on the container adjacent to the elongate transparent zone (4).
2. A medicinal product package (1) as claimed in claim 1, where the access for removing the blister card (5) lying right at the bottom is a first zone (2) of the container which comprises a perforated line (3) and can be detached from the remainder of the container.
3. A medicinal product package (1) as claimed in claim 1 to 2, where the blister card (5) contains the daily dose of medicaments, and the medicaments are disposed in sections (9,10) on the blister card according to the time of day at which they must be taken.
4. A medicinal product package (1) according to claim 1, wherein four to twenty blister cards (5) are present in said package.
5. A medicinal product package (1) according to claim 1, wherein seven to fourteen blister cards (5) are present in said package.
6. A medicinal product package (1) according to claim 1, which additionally comprises a leaflet (7) with patient information located in the container under the stack of blister cards (5) and which leaflet (7) must be removed from the container before said blister card (5) lying right at the bottom can be removed.
7. The use of the medicinal product packaging (1) as claimed in any of claims 1 to 6 for controlling Helicobacter pylori with pantoprazole in conjunction with antibiotics.
8. The use as claimed in claim 7, where pantoprazole is employed in conjunction with amoxicillin, clarithromycin, metronidazole, tinidazole or other antibiotics or therapeutic agents customary in Helicobacter pylori eradication therapy.
9. The use as claimed in claim 8, where the other antibiotics or therapeutic agents customary in Helicobacter pylori eradication therapy comprise bismuth products.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10030318A DE10030318C1 (en) | 2000-06-27 | 2000-06-27 | Pharmaceutical packaging for eradication therapy |
| DE10030318.8 | 2000-06-27 | ||
| PCT/EP2001/007148 WO2002000161A1 (en) | 2000-06-27 | 2001-06-23 | Medicinal product package for eradication therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2412205A1 CA2412205A1 (en) | 2002-01-03 |
| CA2412205C true CA2412205C (en) | 2010-03-30 |
Family
ID=7646356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2412205A Expired - Fee Related CA2412205C (en) | 2000-06-27 | 2001-06-23 | Medicinal product package for eradication therapy |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6988619B2 (en) |
| EP (1) | EP1296633B1 (en) |
| JP (1) | JP4955893B2 (en) |
| KR (1) | KR100801941B1 (en) |
| CN (1) | CN1226981C (en) |
| AT (1) | ATE410131T1 (en) |
| AU (2) | AU8187901A (en) |
| BR (1) | BRPI0112044B8 (en) |
| CA (1) | CA2412205C (en) |
| CY (1) | CY1108672T1 (en) |
| DE (2) | DE10030318C1 (en) |
| DK (1) | DK1296633T3 (en) |
| ES (1) | ES2315299T3 (en) |
| HK (1) | HK1058617A1 (en) |
| MX (1) | MXPA02012824A (en) |
| PL (1) | PL204431B1 (en) |
| PT (1) | PT1296633E (en) |
| SI (1) | SI1296633T1 (en) |
| WO (1) | WO2002000161A1 (en) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6708826B1 (en) * | 2003-04-30 | 2004-03-23 | Warner-Lambert Company, Llc | Packaged supply of individual doses of a personal care product |
| GB0315172D0 (en) * | 2003-06-28 | 2003-08-06 | Aslett Donald | Dispensing pack |
| US7648360B2 (en) * | 2003-07-01 | 2010-01-19 | Align Technology, Inc. | Dental appliance sequence ordering system and method |
| US20050109658A1 (en) * | 2003-11-26 | 2005-05-26 | Bindford James D. | Medication compliance and management device |
| WO2005074898A2 (en) * | 2004-01-28 | 2005-08-18 | Altana Pharma Ag | Composition comprising (s) pantoprazole and an antibiotic for treating helicobacter pylori |
| AT413483B (en) * | 2004-03-11 | 2006-03-15 | Knapp Logistik Automation | AUTOMATIC TABLET FILLING PROCESS AND SYSTEM |
| US8266878B2 (en) | 2004-10-01 | 2012-09-18 | Edge Medical Properties, Llc | System and method for verifying and assembling a multiple prescription package |
| US20110101016A1 (en) * | 2009-09-25 | 2011-05-05 | Edge Medical Properties, Llc | Low vision patient compliant medication management system and method |
| US8712582B1 (en) | 2004-10-01 | 2014-04-29 | Edge Medical Properties, Llc | System and method for combining different tablets into a pouch |
| US7690173B2 (en) * | 2005-09-30 | 2010-04-06 | Edge Medical, Inc. | Multiple prescription production facility |
| US8914298B1 (en) | 2004-10-01 | 2014-12-16 | Edge Medical Properties, Llc | System and method for integrated verification and assembly of multi-script pouches into a housing container |
| US20130299381A9 (en) * | 2004-10-01 | 2013-11-14 | Edge Medical Properties, Llc | Dual dispensing tablet container |
| US8789700B2 (en) * | 2004-10-01 | 2014-07-29 | Edge Medical Properties, Llc | System and method for communicating and inspecting a multiple tablet order |
| US10315450B1 (en) | 2006-10-24 | 2019-06-11 | Edge Medical Properties, Llc | System and method for generating an integrated label for container housing multi-script pouches |
| US9334096B2 (en) | 2004-10-01 | 2016-05-10 | Edge Medical Properties, Llc | Multiple inspection system and method that inspects different medications |
| US8146747B2 (en) * | 2004-10-01 | 2012-04-03 | Edge Medical Properties, Llc | Tablet dispensing container |
| US8123036B2 (en) | 2004-10-01 | 2012-02-28 | Edge Medical Properties, Llc | Pill assembly for pill packaging and delivery systems |
| US9015058B2 (en) | 2004-10-01 | 2015-04-21 | Edge Medical Properties, Llc | Matrix based dosage scheduling |
| US9245304B2 (en) * | 2004-10-01 | 2016-01-26 | Edge Medical Properties, Llc | Manufacturing separable pouches with a center cut blade |
| US9141764B2 (en) | 2010-11-12 | 2015-09-22 | Edge Medical Properties, Llc | System and method for online integrated multiple tablet ordering |
| US9710866B2 (en) * | 2005-09-30 | 2017-07-18 | Edge Medical, Llc | System and method for processing a multiple prescription order |
| US9238518B2 (en) | 2004-10-01 | 2016-01-19 | Edge Medical Properties, Llc | Inspection system and method with a control process that inspects different medications |
| US8972288B2 (en) | 2004-10-01 | 2015-03-03 | Edge Medical Properties, Llc | System and method for online matrix-based dosage scheduling |
| US7464816B2 (en) * | 2004-10-14 | 2008-12-16 | Sage Products, Inc. | Product dispensing system |
| US9650173B2 (en) | 2004-10-14 | 2017-05-16 | Sage Products, Llc | Product dispensing system |
| DE102004059539B4 (en) * | 2004-12-09 | 2008-12-18 | Gass, Johann | Packaging arrangement for a drug |
| ATE503699T1 (en) | 2005-02-14 | 2011-04-15 | Mcneil Ppc Inc | PACKAGING FOR A PERSONAL CARE PRODUCT |
| US20070095850A1 (en) * | 2005-10-27 | 2007-05-03 | Meyer Daniel D | Multiple medication dispensing system |
| US7581642B2 (en) * | 2006-01-09 | 2009-09-01 | Anderson Packaging, Inc. | Child-resistant, senior-friendly unit dose container |
| US7806270B2 (en) * | 2007-08-16 | 2010-10-05 | Anderson Packaging, Inc. | Child-resistant, senior-friendly unit dose container |
| US7617935B2 (en) * | 2008-01-10 | 2009-11-17 | Anderson Packaging, Inc. | Reusable child-resistant, senior friendly unit dose container |
| US9083474B2 (en) * | 2008-04-25 | 2015-07-14 | Qualcomm Incorporated | Multimedia broadcast forwarding systems and methods |
| US10435192B2 (en) | 2011-05-16 | 2019-10-08 | Edge Medical Properties, Llc | Multiple inspection system and method that inspects different medications |
| US10045909B2 (en) * | 2012-03-30 | 2018-08-14 | Aesynt Incorporated | Storage apparatus with support structures |
| US20140299490A1 (en) * | 2013-04-04 | 2014-10-09 | The Procter & Gamble Company | Package for a Medicament |
| US8955696B2 (en) * | 2012-06-08 | 2015-02-17 | Tina Ting-Yuan Wang | Storage systems for milk bags |
| RU2545687C1 (en) * | 2014-04-09 | 2015-04-10 | Юрий Александрович Лаврентьев | Method for helicobacter pylori eradication of gastroduodenal zone |
| EP3135602A1 (en) * | 2015-08-25 | 2017-03-01 | Bayer Pharma Aktiengesellschaft | Blister pack |
| WO2017044628A2 (en) | 2015-09-08 | 2017-03-16 | Accredo Health Group, Inc. | Medication dispensing system |
| EP3147233A1 (en) * | 2015-09-22 | 2017-03-29 | Bayer Pharma Aktiengesellschaft | Single blister packages for optimized stacking |
| GB201602470D0 (en) * | 2016-02-11 | 2016-03-30 | Glaxosmithkline Intellectual Property Man Ltd | Healthcare product package |
| JP7149186B2 (en) * | 2016-02-24 | 2022-10-06 | セルジーン コーポレイション | Nested packaging for pharmaceutical products and method of distributing pharmaceutical products using the same |
| US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
| US10682284B2 (en) * | 2017-05-18 | 2020-06-16 | Thomas Eric Carson | Pill dispensing apparatus and method for automatically dispensing pills |
| USD874944S1 (en) * | 2018-10-05 | 2020-02-11 | Thrifty Drug Stores, Inc. | Cardboardless blister package for pills |
| US11468665B2 (en) * | 2019-08-26 | 2022-10-11 | United States Postal Service | Automated measurement utility |
| JP7276228B2 (en) * | 2020-04-01 | 2023-05-18 | ニプロ株式会社 | packaging box |
| WO2023242796A1 (en) * | 2022-06-15 | 2023-12-21 | Varoli Giovan Battista | Box for the supply of food products for dysphagic users |
| US20240092549A1 (en) * | 2022-09-19 | 2024-03-21 | Altria Client Services Llc | Insert with undercuts |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3308962A (en) * | 1965-05-10 | 1967-03-14 | Austin U Bryant | Pill organizer and method |
| US3497982A (en) * | 1968-11-22 | 1970-03-03 | Ciba Geigy Corp | Package and method for dispensing of pharmaceutical preparations |
| US4736849A (en) * | 1983-12-19 | 1988-04-12 | Leonard Walter G | Calendar-oriented pill dispenser |
| US4811845A (en) * | 1987-10-06 | 1989-03-14 | Baggett Jobeth | Medication compliance packaging system and procedure |
| US4889238A (en) * | 1989-04-03 | 1989-12-26 | The Procter & Gamble Company | Medicament package for increasing compliance with complex therapeutic regimens |
| US5265759A (en) * | 1990-08-02 | 1993-11-30 | Wilkinson Sword Gesellschaft Mit Beschrankter Haftung | Arrangement for the accommodation and sales display of razor blade units of wet razors packaged in dispensers |
| US5542539A (en) * | 1995-04-04 | 1996-08-06 | Ethicon Endo-Surgery, Inc. | Container for quick release packages for surgical instruments |
| US5945124A (en) * | 1995-07-05 | 1999-08-31 | Byk Gulden Chemische Fabrik Gmbh | Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole |
| US5788974A (en) | 1996-09-11 | 1998-08-04 | D'amico; Steven A. | Helicobacter pylori treatment compliance pack |
| DE29719070U1 (en) * | 1996-10-29 | 1998-05-14 | Byk Gulden Lomberg Chem Fab | Blister for combination therapy |
| US6564945B1 (en) * | 1997-07-14 | 2003-05-20 | Robert E. Weinstein | Medication assemblage for use in sinusitis treatment regimens |
| FR2782070B1 (en) * | 1998-08-05 | 2000-10-13 | Jacques Labat | DISPENSER FOR SMALL HARDWARE ARTICLES AND SUPPORT FOR SUCH ARTICLES FOR SUPPLYING THE SAME |
| DE29913195U1 (en) | 1999-07-28 | 2000-02-10 | Kugler Astrid | Combination pack for medication |
-
2000
- 2000-06-27 DE DE10030318A patent/DE10030318C1/en not_active Expired - Lifetime
-
2001
- 2001-06-23 AU AU8187901A patent/AU8187901A/en active Pending
- 2001-06-23 JP JP2002504944A patent/JP4955893B2/en not_active Expired - Fee Related
- 2001-06-23 DK DK01960370T patent/DK1296633T3/en active
- 2001-06-23 WO PCT/EP2001/007148 patent/WO2002000161A1/en active Search and Examination
- 2001-06-23 AT AT01960370T patent/ATE410131T1/en active
- 2001-06-23 KR KR1020027017810A patent/KR100801941B1/en not_active IP Right Cessation
- 2001-06-23 EP EP01960370A patent/EP1296633B1/en not_active Expired - Lifetime
- 2001-06-23 DE DE60136068T patent/DE60136068D1/en not_active Expired - Lifetime
- 2001-06-23 PT PT01960370T patent/PT1296633E/en unknown
- 2001-06-23 US US10/297,257 patent/US6988619B2/en not_active Expired - Lifetime
- 2001-06-23 CA CA2412205A patent/CA2412205C/en not_active Expired - Fee Related
- 2001-06-23 SI SI200130890T patent/SI1296633T1/en unknown
- 2001-06-23 MX MXPA02012824A patent/MXPA02012824A/en active IP Right Grant
- 2001-06-23 CN CNB018119808A patent/CN1226981C/en not_active Expired - Fee Related
- 2001-06-23 AU AU2001281879A patent/AU2001281879B2/en not_active Ceased
- 2001-06-23 BR BRPI0112044A patent/BRPI0112044B8/en not_active IP Right Cessation
- 2001-06-23 ES ES01960370T patent/ES2315299T3/en not_active Expired - Lifetime
- 2001-06-23 PL PL358291A patent/PL204431B1/en unknown
-
2004
- 2004-02-26 HK HK04101388A patent/HK1058617A1/en not_active IP Right Cessation
-
2008
- 2008-12-17 CY CY20081101457T patent/CY1108672T1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL358291A1 (en) | 2004-08-09 |
| BR0112044B1 (en) | 2013-11-12 |
| CA2412205A1 (en) | 2002-01-03 |
| JP2004500967A (en) | 2004-01-15 |
| ES2315299T3 (en) | 2009-04-01 |
| MXPA02012824A (en) | 2003-05-14 |
| BRPI0112044B8 (en) | 2017-04-25 |
| DE60136068D1 (en) | 2008-11-20 |
| CY1108672T1 (en) | 2014-04-09 |
| HK1058617A1 (en) | 2004-05-28 |
| EP1296633B1 (en) | 2008-10-08 |
| JP4955893B2 (en) | 2012-06-20 |
| SI1296633T1 (en) | 2009-04-30 |
| AU8187901A (en) | 2002-01-08 |
| PT1296633E (en) | 2009-01-08 |
| ATE410131T1 (en) | 2008-10-15 |
| WO2002000161A1 (en) | 2002-01-03 |
| US20030136698A1 (en) | 2003-07-24 |
| CN1438866A (en) | 2003-08-27 |
| DK1296633T3 (en) | 2009-02-09 |
| KR20030018010A (en) | 2003-03-04 |
| BR0112044A (en) | 2003-06-10 |
| CN1226981C (en) | 2005-11-16 |
| DE10030318C1 (en) | 2002-02-28 |
| AU2001281879B2 (en) | 2006-04-06 |
| EP1296633A1 (en) | 2003-04-02 |
| US6988619B2 (en) | 2006-01-24 |
| KR100801941B1 (en) | 2008-02-12 |
| PL204431B1 (en) | 2010-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2412205C (en) | Medicinal product package for eradication therapy | |
| AU2001281879A1 (en) | Medicinal product package for eradication therapy | |
| JP2004500967A5 (en) | ||
| US4887790A (en) | Troche mold and dispenser | |
| US6375956B1 (en) | Strip pack | |
| EP0391459B1 (en) | Medicament package for increasing compliance with complex therapeutic regimens | |
| US6981592B2 (en) | Product packaging material for individual temporary storage of pharmaceutical products | |
| CN1860072A (en) | Dispensing containers | |
| JP2013022457A (en) | Administration method and packaging container for dosage unit | |
| US5542236A (en) | Method of dispensing unit doses of medications and associated products | |
| GB2489921A (en) | Seal / container arrangement with cavity display panel(s) | |
| US3461643A (en) | Method and apparatus for counting and dispensing solid oral medication | |
| WO2004087038A1 (en) | Kit for pharmaceutical use | |
| US20180282040A1 (en) | Individual blister packs for optimized stacking | |
| JPH0732401Y2 (en) | Tablet packaging machine packaging equipment | |
| JP3032284U (en) | Delivery medicine box |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20200831 |